Ruxolitinib
Sign in to save this workspacePrimary targets: JAK1, JAK2, JAK3, TYK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.25
Gini
0.592
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ruxolitinib. Strongest target: JAK2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK2 | 100.0% | 0.0% |
| 2 | JAK3 | 99.2% | 0.8% |
| 3 | TYK2 | 99.0% | 1.0% |
| 4 | JAK1 | 96.7% | 3.3% |
| 5 | CAMK2A | 93.0% | 7.0% |
| 6 | CAMK2D | 90.5% | 9.5% |
| 7 | STK38L_NDR2 | 90.0% | 10.0% |
| 8 | DMPK2 | 87.1% | 12.9% |
| 9 | STK38_NDR1 | 86.6% | 13.4% |
| 10 | ACK1 | 78.5% | 21.5% |
| 11 | TRKC | 75.2% | 24.8% |
| 12 | LATS1 | 71.2% | 28.8% |
| 13 | CDK8_CYCLIN_C | 69.0% | 31.0% |
| 14 | CDK19_CYCLIN_C | 66.6% | 33.4% |
| 15 | ROCK1 | 63.6% | 36.4% |
| 16 | LRRK2 | 63.0% | 37.0% |
| 17 | MEKK3 | 57.0% | 43.0% |
| 18 | LIMK1 | 54.3% | 45.7% |
| 19 | MEKK2 | 52.6% | 47.4% |
| 20 | ALK | 52.1% | 47.9% |
Selectivity landscape
Where Ruxolitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ruxolitinib.
Atlas insights for Ruxolitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1944.94 | |
| ALLOGRAFT_REJECTION | 4629.13 | |
| ANDROGEN_RESPONSE | 1570.16 | |
| ANGIOGENESIS | 697.62 | |
| APICAL_JUNCTION | 4594.60 | |
| APICAL_SURFACE | 601.98 | |
| APOPTOSIS | 5032.48 | |
| BILE_ACID_METABOLISM | 552.15 | |
| CHOLESTEROL_HOMEOSTASIS | 671.04 | |
| COAGULATION | 457.31 | |
| COMPLEMENT | 2884.21 | |
| DNA_REPAIR | 1082.61 | |
| E2F_TARGETS | 3759.85 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2077.49 | |
| ESTROGEN_RESPONSE_EARLY | 2927.63 | |
| ESTROGEN_RESPONSE_LATE | 2697.87 | |
| FATTY_ACID_METABOLISM | 336.62 | |
| G2M_CHECKPOINT | 3818.71 | |
| GLYCOLYSIS | 2102.98 | |
| HEDGEHOG_SIGNALING | 624.96 | |
| HEME_METABOLISM | 1489.43 | |
| HYPOXIA | 2851.16 | |
| IL2_STAT5_SIGNALING | 2072.35 | |
| IL6_JAK_STAT3_SIGNALING | 4193.79 | |
| INFLAMMATORY_RESPONSE | 3516.34 | |
| INTERFERON_ALPHA_RESPONSE | 679.49 | |
| INTERFERON_GAMMA_RESPONSE | 4511.69 | |
| KRAS_SIGNALING_DN | 966.58 | |
| KRAS_SIGNALING_UP | 1687.23 | |
| MITOTIC_SPINDLE | 3769.15 | |
| MTORC1_SIGNALING | 2202.99 | |
| MYC_TARGETS_V1 | 2263.98 | |
| MYC_TARGETS_V2 | 569.98 | |
| MYOGENESIS | 3147.62 | |
| NOTCH_SIGNALING | 210.84 | |
| OXIDATIVE_PHOSPHORYLATION | 564.52 | |
| P53_PATHWAY | 2390.09 | |
| PANCREAS_BETA_CELLS | 238.45 | |
| PEROXISOME | 881.45 | |
| PI3K_AKT_MTOR_SIGNALING | 5937.58 | |
| PROTEIN_SECRETION | 1707.31 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 212.33 | |
| SPERMATOGENESIS | 1338.19 | |
| TGF_BETA_SIGNALING | 1554.07 | |
| TNFA_SIGNALING_VIA_NFKB | 3678.35 | |
| UNFOLDED_PROTEIN_RESPONSE | 1336.48 | |
| UV_RESPONSE_DN | 3172.86 | |
| UV_RESPONSE_UP | 2662.98 | |
| WNT_BETA_CATENIN_SIGNALING | 1625.10 | |
| XENOBIOTIC_METABOLISM | 1076.93 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.865 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.853 |
| SRR23303752 | — | 0.845 |
| aMVAC.P_005_TURBT_S223 | — | 0.838 |
| SRR12202498 | — | 0.837 |
Annotations
Sign in to read and post annotations.
Loading…